212 related articles for article (PubMed ID: 11251009)
1. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.
Villafranca E; Okruzhnov Y; Dominguez MA; García-Foncillas J; Azinovic I; Martínez E; Illarramendi JJ; Arias F; Martínez Monge R; Salgado E; Angeletti S; Brugarolas A
J Clin Oncol; 2001 Mar; 19(6):1779-86. PubMed ID: 11251009
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
Hur H; Kang J; Kim NK; Min BS; Lee KY; Shin SJ; Keum KC; Choi J; Kim H; Choi SH; Lee MY
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):669-76. PubMed ID: 20932673
[TBL] [Abstract][Full Text] [Related]
3. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Arrazubi V; Suárez J; Guerrero D; Gómez M; Viúdez A; Arias F; Balén E; Vera R
Colorectal Dis; 2013 Apr; 15(4):428-35. PubMed ID: 22958523
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
Tsuji T; Hidaka S; Sawai T; Nakagoe T; Yano H; Haseba M; Komatsu H; Shindou H; Fukuoka H; Yoshinaga M; Shibasaki S; Nanashima A; Yamaguchi H; Yasutake T; Tagawa Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3700-4. PubMed ID: 14506161
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
Jakob C; Liersch T; Meyer W; Baretton GB; Schwabe W; Häusler P; Kulle B; Becker H; Aust DE
Am J Surg Pathol; 2006 Sep; 30(9):1169-74. PubMed ID: 16931962
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
8. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J
Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer.
Nelson B; Carter JV; Eichenberger MR; Netz U; Galandiuk S
Surgery; 2016 Nov; 160(5):1326-1332. PubMed ID: 27423551
[TBL] [Abstract][Full Text] [Related]
10. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
Marcuello E; Altés A; del Rio E; César A; Menoyo A; Baiget M
Int J Cancer; 2004 Dec; 112(5):733-7. PubMed ID: 15386371
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.
Toriumi F; Kubota T; Saikawa Y; Yoshida M; Otani Y; Watanabe M; Kumai K; Kitajima M
Anticancer Res; 2004; 24(4):2455-63. PubMed ID: 15330198
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
14. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
Iacopetta B; Grieu F; Joseph D; Elsaleh H
Br J Cancer; 2001 Sep; 85(6):827-30. PubMed ID: 11556832
[TBL] [Abstract][Full Text] [Related]
15. The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer.
Ott K; Vogelsang H; Marton N; Becker K; Lordick F; Kobl M; Schuhmacher C; Novotny A; Mueller J; Fink U; Ulm K; Siewert JR; Höfler H; Keller G
Int J Cancer; 2006 Dec; 119(12):2885-94. PubMed ID: 16929515
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.
Stoehlmacher J; Goekkurt E; Mogck U; Aust DE; Kramer M; Baretton GB; Liersch T; Ehninger G; Jakob C
Cancer Lett; 2008 Dec; 272(2):221-5. PubMed ID: 18722050
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.
Páez D; Paré L; Altés A; Sancho-Poch FJ; Petriz L; Garriga J; Monill JM; Salazar J; del Rio E; Barnadas A; Marcuello E; Baiget M
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1681-9. PubMed ID: 20165956
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
Etienne MC; Chazal M; Laurent-Puig P; Magné N; Rosty C; Formento JL; Francoual M; Formento P; Renée N; Chamorey E; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
J Clin Oncol; 2002 Jun; 20(12):2832-43. PubMed ID: 12065560
[TBL] [Abstract][Full Text] [Related]
20. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.
Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E
Eur J Cancer; 2005 Sep; 41(14):2176-83. PubMed ID: 16182121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
